It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cell death mechanisms in T lymphocytes vary according to their developmental stage, cell subset and activation status. The cell death control mechanisms of mucosal-associated invariant T (MAIT) cells, a specialized T cell population, are largely unknown. Here we report that MAIT cells express key necroptotic machinery; receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL) protein, in abundance. Despite this, we discovered that the loss of RIPK3, but not necroptotic effector MLKL or apoptotic caspase-8, specifically increased MAIT cell abundance at steady-state in the thymus, spleen, liver and lungs, in a cell-intrinsic manner. In contrast, over the course of infection with Francisella tularensis, RIPK3 deficiency did not impact the magnitude of the expansion nor contraction of MAIT cell pools. These findings suggest that, distinct from conventional T cells, the accumulation of MAIT cells is restrained by RIPK3 signalling, likely prior to thymic egress, in a manner independent of canonical apoptotic and necroptotic cell death pathways.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d)
2 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
4 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
5 Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
6 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Royal Children’s Hospital Parkville, Murdoch Children’s Research Institute, Parkville, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346); University of Melbourne, Department of Paediatrics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Shanghai Huaota Biopharm, Department of Drug Discovery, Shanghai, China (GRID:grid.1008.9)
8 Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)